Drugs / TIX100
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07675590 Comparator | Jun → Oct 2026 expected | obesity disorder | TIXiMED, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06800729 Comparator | Jan → May 2025 overdue | — | TIXiMED, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIX100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07675590 ↗ |
| Action | Inhibit | “inhibitor of thioredoxin-interacting protein” NCT06800729 ↗ |
| Route | Oral | “Orally Administered TIX100” NCT06800729 ↗ |